Table 2 Response rate.

From: Efficacy, safety and prognostic factors in patients with refractory metastatic colorectal cancer treated with trifluridine/tipiracil plus bevacizumab in a real-world setting

Response, n (%)

N = 31

Best overall response

CR

0

PR

1 (3.2)

SD

15 (48.4)

PD

15 (48.4)

ORR (CR + PR)

1 (3.2)

DCR (CR + PR + SD)

16 (51.6)

  1. CR complete response, DCR disease control rate, ORR overall response rate, PD progressive disease, PR partial response, SD stable disease.
Back to article page